MX2020010183A - Variantes y composiciones del lfa3 y sus usos. - Google Patents

Variantes y composiciones del lfa3 y sus usos.

Info

Publication number
MX2020010183A
MX2020010183A MX2020010183A MX2020010183A MX2020010183A MX 2020010183 A MX2020010183 A MX 2020010183A MX 2020010183 A MX2020010183 A MX 2020010183A MX 2020010183 A MX2020010183 A MX 2020010183A MX 2020010183 A MX2020010183 A MX 2020010183A
Authority
MX
Mexico
Prior art keywords
lfa3
variants
compositions
polypeptide molecules
variant
Prior art date
Application number
MX2020010183A
Other languages
English (en)
Inventor
Jeffrey A Bluestone
Natasha Kay Crellin
Lauren Kate Ely
Reyes Jason Robles
Chia Chi Ho
Eleonora Trotta
Qizhi Tang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020010183A publication Critical patent/MX2020010183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70507—C2D

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La presente invención se refiere a moléculas del polipéptido de LFA3, por ejemplo, moléculas del polipéptido de fusión variante LFA3. La invención incluye usos y métodos asociados para usar las moléculas del polipéptido de LFA3.
MX2020010183A 2018-03-29 2019-03-25 Variantes y composiciones del lfa3 y sus usos. MX2020010183A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650022P 2018-03-29 2018-03-29
US201862783986P 2018-12-21 2018-12-21
PCT/US2019/023883 WO2019190984A1 (en) 2018-03-29 2019-03-25 Lfa3 variants and compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010183A true MX2020010183A (es) 2022-11-28

Family

ID=66049729

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010183A MX2020010183A (es) 2018-03-29 2019-03-25 Variantes y composiciones del lfa3 y sus usos.
MX2022014899A MX2022014899A (es) 2018-03-29 2020-09-29 Variantes y composiciones del lfa3 y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014899A MX2022014899A (es) 2018-03-29 2020-09-29 Variantes y composiciones del lfa3 y sus usos.

Country Status (16)

Country Link
US (1) US12103958B2 (es)
EP (1) EP3774863A1 (es)
JP (1) JP2021519758A (es)
KR (1) KR20200136465A (es)
CN (1) CN112236446A (es)
AU (2) AU2019242451B2 (es)
BR (1) BR112020019368A2 (es)
CA (1) CA3094756A1 (es)
CL (1) CL2020002507A1 (es)
CO (1) CO2020013557A2 (es)
IL (1) IL277441A (es)
MX (2) MX2020010183A (es)
PE (1) PE20211235A1 (es)
PH (1) PH12020551582A1 (es)
SG (1) SG11202009539XA (es)
WO (1) WO2019190984A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5547853A (en) * 1991-03-12 1996-08-20 Biogen, Inc. CD2-binding domain of lymphocyte function associated antigen 3
ES2181673T3 (es) 1991-05-01 2003-03-01 Jackson H M Found Military Med Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
AU660312B2 (en) 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DK0786255T3 (da) * 1991-10-07 2002-04-15 Biogen Inc Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
EP1109570B1 (en) 1998-08-31 2005-10-19 Biogen, Inc. Modulation of memory effector t-cells with a cd2 binding agent
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0303826A2 (hu) * 2001-02-01 2004-03-01 Biogen, Inc. Eljárások bőr rendellenességeinek kezelésére vagy prevenciójára CD2-kötőágensek alkalmazásával
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK2330201T3 (en) 2003-10-22 2017-07-24 Keck Graduate Inst PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CN101089180A (zh) * 2006-04-26 2007-12-19 上海中信国健药业有限公司 一种重组lfa3基因,及其融合基因与产物
US7994290B2 (en) 2007-01-24 2011-08-09 Kyowa Hakko Kirin Co., Ltd Effector function enhanced recombinant antibody composition
DK2608796T3 (en) 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
KR20140021799A (ko) 2012-08-09 2014-02-20 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도

Also Published As

Publication number Publication date
KR20200136465A (ko) 2020-12-07
SG11202009539XA (en) 2020-10-29
PE20211235A1 (es) 2021-07-08
AU2024205663A1 (en) 2024-08-29
WO2019190984A1 (en) 2019-10-03
EP3774863A1 (en) 2021-02-17
CA3094756A1 (en) 2019-10-03
AU2019242451B2 (en) 2024-05-09
IL277441A (en) 2020-11-30
JP2021519758A (ja) 2021-08-12
BR112020019368A2 (pt) 2021-02-17
US12103958B2 (en) 2024-10-01
PH12020551582A1 (en) 2021-09-13
MX2022014899A (es) 2023-01-04
CO2020013557A2 (es) 2020-11-10
CL2020002507A1 (es) 2021-02-26
AU2019242451A1 (en) 2020-11-12
CN112236446A (zh) 2021-01-15
US20210032308A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX2020006322A (es) Proteinas de fusion il-2 fc modificadas.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
EP3957723A3 (en) Engineered ligase variants
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018001497A (es) Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
CR20230163A (es) ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
PH12020551716A1 (en) Anti-ror antibody constructs
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2020007628A (es) Composiciones y metodos de uso.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
EP4001310A3 (en) Ion channel modulators and uses thereof
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2022014899A (es) Variantes y composiciones del lfa3 y sus usos.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations